Dermira Inc. (NASDAQ:DERM) fell 3.6% during trading on Monday . The company traded as low as $29.52 and last traded at $29.81, with a volume of 150,498 shares traded. The stock had previously closed at $30.91.

A number of brokerages have recently commented on DERM. Needham & Company LLC raised their price objective on shares of Dermira from $42.00 to $46.00 and gave the stock a “buy” rating in a research note on Thursday, June 2nd. Leerink Swann reaffirmed a “buy” rating and set a $47.00 price objective (up previously from $46.00) on shares of Dermira in a research note on Thursday, June 2nd. Wedbush raised their price objective on shares of Dermira from $42.00 to $46.00 and gave the stock an “outperform” rating in a research note on Thursday, June 2nd. Finally, Zacks Investment Research raised shares of Dermira from a “sell” rating to a “hold” rating in a research note on Friday, July 8th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Dermira has a consensus rating of “Buy” and an average target price of $40.71.

The company’s market cap is $882.53 million. The stock’s 50 day moving average price is $30.04 and its 200-day moving average price is $26.57.

Dermira (NASDAQ:DERM) last issued its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.95) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.94) by $0.01. Equities analysts expect that Dermira Inc. will post ($3.51) earnings per share for the current fiscal year.

In other Dermira news, VP Christopher M. Griffith sold 4,405 shares of the business’s stock in a transaction that occurred on Monday, June 13th. The stock was sold at an average price of $30.16, for a total value of $132,854.80. Following the completion of the sale, the vice president now owns 48,043 shares in the company, valued at $1,448,976.88. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Eugene A. Bauer sold 2,500 shares of the business’s stock in a transaction that occurred on Monday, May 2nd. The shares were sold at an average price of $25.09, for a total value of $62,725.00. The disclosure for this sale can be found here.

A number of large investors have recently modified their holdings of the stock. Wells Fargo & Company MN boosted its stake in shares of Dermira by 424.6% in the fourth quarter. Wells Fargo & Company MN now owns 41,036 shares of the biopharmaceutical company’s stock worth $1,420,000 after buying an additional 33,213 shares in the last quarter. Morgan Stanley boosted its stake in shares of Dermira by 82.2% in the fourth quarter. Morgan Stanley now owns 42,767 shares of the biopharmaceutical company’s stock worth $1,480,000 after buying an additional 19,299 shares in the last quarter. Jennison Associates boosted its stake in shares of Dermira by 98.7% in the third quarter. Jennison Associates now owns 1,013,343 shares of the biopharmaceutical company’s stock worth $23,651,000 after buying an additional 503,237 shares in the last quarter. Finally, Jennison Associates LLC boosted its stake in shares of Dermira by 8.3% in the fourth quarter. Jennison Associates LLC now owns 1,097,201 shares of the biopharmaceutical company’s stock worth $37,974,000 after buying an additional 83,858 shares in the last quarter.

Dermira, Inc is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.